Journal Article Summary
The article investigates the effectiveness of two medications, phenobarbital and levetiracetam, in treating neonatal abstinence syndrome (NAS) in infants born to mothers with substance use disorders. NAS can cause a range of withdrawal symptoms in newborns, and while phenobarbital is commonly used, concerns exist regarding its long-term side effects. This study is significant as it explores a potential alternative treatment that may have fewer adverse effects, thereby improving the care of vulnerable infants.
In this randomized clinical trial, 82 infants diagnosed with NAS were treated in a neonatal intensive care unit over one year. The infants were divided into two groups, with one receiving phenobarbital and the other levetiracetam as secondary treatments after initial morphine therapy. The study found no significant differences in hospitalization duration, re-hospitalization rates, or complications between the two groups, suggesting that levetiracetam may be a viable substitute for phenobarbital in managing NAS.
However, the study has limitations, including a small sample size and a lack of long-term follow-up to assess potential side effects. Parents and caregivers should discuss these findings with healthcare professionals, particularly regarding the choice of medication for treating NAS. It is essential to consider the individual needs of each infant and the potential implications of using either medication, especially in terms of long-term health outcomes.
Medication Safety Note
This journal article summary is provided for educational purposes only and is not medical advice. Always consult a licensed healthcare professional before starting, stopping, or changing any medication.
Article Cited
- Jamali Zahra, Molaei-Farsangi Mohammad Hosein, Ahmadipour Habibeh, Bahmanbijari Bahareh, Sabzevari Fatemeh, Parizi Zahra Daei. Comparison of the effect of phenobarbital & levetiracetam in the treatment of neonatal abstinence syndrome (NAS) as adjuvant treatment in neonates admitted to the neonatal intensive care unit: a randomized clinical trial. BMC Pregnancy and Childbirth 2024. DOI: 10.1186/s12884-024-06433-y. PMID: 38580935. PMCID: PMC10996075.
Featured Pill Pals Product
Levetiracetam 500 mg Tablets --- Generic For Keppra --- Rising Pharma
Levetiracetam 500 mg Tablets — Generic For Keppra — Rising Pharma is available through Pill Pals Pharmacy with cash-pay pharmacy pricing and free shipping where available. Prescription required.
Request a prescription transfer and our pharmacy team will help coordinate the next step.
